[{"orgOrder":0,"company":"Merz Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"SNAP25","graph1":"Undisclosed","graph2":"Phase II","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Merz Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Merz Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Merz Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"SNAP25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Merz Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merz Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merz Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Teijin Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"SNAP25","graph1":"Neurology","graph2":"Approved FDF","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merz Pharma \/ Merz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Merz Pharma \/ Merz Pharma"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"SNAP25","graph1":"Neurology","graph2":"Approved FDF","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merz Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merz Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"SNAP25","graph1":"Neurology","graph2":"Approved FDF","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merz Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merz Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Teijin Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"SNAP25","graph1":"Neurology","graph2":"Approved FDF","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merz Pharma \/ Merz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Merz Pharma \/ Merz Pharma"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Vensica Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"ISRAEL","productType":"Protein","year":"2022","type":"Partnership","leadProduct":"Incobotulinumtoxin A","moa":"SNAP25","graph1":"Urology","graph2":"Phase III","graph3":"Merz Pharma","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0.02,"dosageForm":"Intramuscular Injection","sponsorNew":"Merz Pharma \/ Merz Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Merz Pharma \/ Merz Pharma"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Acorda Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Etilevodopa","moa":"Dopamine D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Merz Pharma","amount2":0.19,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.19,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Merz Pharma \/ Merz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Merz Pharma \/ Merz Pharma"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Acorda Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Etilevodopa","moa":"Dopamine D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Merz Pharma","amount2":0.19,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.19,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Merz Pharma \/ Merz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Merz Pharma \/ Merz Pharma"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Hong Kong Winhealth Pharma Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"L-Ornithine L-aspartate","moa":"Ammonia detoxification","graph1":"Neurology","graph2":"Approved FDF","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merz Pharma \/ Hong Kong Winhealth Pharma Group","highestDevelopmentStatusID":"15","companyTruncated":"Merz Pharma \/ Hong Kong Winhealth Pharma Group"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Merz Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"SNAP25","graph1":"Sleep","graph2":"Phase IV","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merz Pharma \/ Merz Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Merz Pharma \/ Merz Pharma"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Merz Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"SNAP25","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merz Pharma \/ Merz Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Merz Pharma \/ Merz Pharma"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Merz Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"SNAP25","graph1":"Neurology","graph2":"Phase IV","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merz Pharma \/ Merz Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Merz Pharma \/ Merz Pharma"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Merz Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HYDROXYPROPYLMETHYLCELLULOSE","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merz Pharma \/ Merz Therapeutics","highestDevelopmentStatusID":"11","companyTruncated":"Merz Pharma \/ Merz Therapeutics"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Merz Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merz Pharma \/ Merz Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Merz Pharma \/ Merz Pharma"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Merz Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merz Pharma \/ Merz Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Merz Pharma \/ Merz Pharma"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase II","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merz Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Merz Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Merz Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"SNAP25","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Solution","sponsorNew":"Merz Pharma \/ Merz Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Merz Pharma \/ Merz Pharma"},{"orgOrder":0,"company":"Merz Aesthetics","sponsor":"Merz Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"SNAP25","graph1":"Dermatology","graph2":"Phase II","graph3":"Merz Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merz Aesthetics \/ Merz Aesthetics","highestDevelopmentStatusID":"8","companyTruncated":"Merz Aesthetics \/ Merz Aesthetics"},{"orgOrder":0,"company":"Merz Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Undisclosed","graph2":"Phase II","graph3":"Merz Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Powder For Solution","sponsorNew":"Merz Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Merz Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"SNAP25","graph1":"Neurology","graph2":"Phase II","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merz Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Merz Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Merz Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"SNAP25","graph1":"Dermatology","graph2":"Phase I","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merz Pharma \/ Merz Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Merz Pharma \/ Merz Therapeutics"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase I","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merz Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Merz Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Merz Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HYDROXYPROPYLMETHYLCELLULOSE","moa":"Hydroxylapatite","graph1":"Dermatology","graph2":"Phase I","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Merz Pharma \/ Merz Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Merz Pharma \/ Merz Therapeutics"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Pantovigar Vegan","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merz Pharma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Merz Pharma \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Merz Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Xeomin (incobotulinumtoxinA) is a SNAP-25 inhibitor protein drug candidate which is approved for the treatment of chronic sialorrhea.

                          Product Name : Xeomin

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          June 26, 2025

                          Lead Product(s) : Incobotulinumtoxin A

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Recipient : Teijin Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Merz purchases substantially all of the assets of Acorda, including the rights to Inbrija (levodopa inhalation powder), which is used when needed for OFF episodes in adults with Parkinson's disease.

                          Product Name : Inbrija

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          October 07, 2024

                          Lead Product(s) : Etilevodopa

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Recipient : Acorda Therapeutics

                          Deal Size : $185.0 million

                          Deal Type : Acquisition

                          blank

                          03

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Merz Therapeutics will acquire Acorda's assets, including Inbrija (levodopa inhalation) for OFF episodes in Parkinson’s and Ampyra (dalfampridine).

                          Product Name : Inbrija

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          February 04, 2024

                          Lead Product(s) : Etilevodopa

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Recipient : Acorda Therapeutics

                          Deal Size : $185.0 million

                          Deal Type : Acquisition

                          blank

                          04

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          October 19, 2023

                          Lead Product(s) : Incobotulinumtoxin A

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          July 13, 2023

                          Lead Product(s) : Pantovigar Vegan

                          Therapeutic Area : Dermatology

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          June 01, 2023

                          Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase I

                          Recipient : Kalpna Kay Durairaj

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          March 24, 2023

                          Lead Product(s) : Botulinum toxin type A

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          March 17, 2023

                          Lead Product(s) : Botulinum toxin type A

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          October 18, 2022

                          Lead Product(s) : Incobotulinumtoxin A

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          September 13, 2022

                          Lead Product(s) : Incobotulinumtoxin A

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase IV

                          Recipient : King, David, MD

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank